Early initiation of low-dose gilteritinib maintenance improves posttransplant outcomes in patients with R/R FLT3mut AML.

Toshiki TeraoKen-Ichi MatsuokaHiroko UedaAkifumi MatsumuraChisato MatsubaraKaho KondoTakumi KondoHideaki FujiwaraNoboru AsadaDaisuke EnnishiYoshinobu MaedaKeiko FujiiNobuharu FujiiYoshinobu Maeda

Published in: Blood advances (2023)

Keyphrases

acute myeloid leukemia
low dose
high dose
allogeneic hematopoietic stem cell transplantation
tyrosine kinase
type diabetes
metabolic syndrome
adipose tissue
glycemic control
weight loss